Separately, Needham & Company LLC dropped their price objective on Heron Therapeutics from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Wednesday.
Heron Therapeutics Stock Performance
Insider Buying and Selling
In other Heron Therapeutics news, CEO Craig A. Collard bought 150,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The shares were acquired at an average cost of $0.92 per share, with a total value of $138,000.00. Following the acquisition, the chief executive officer now owns 186,496 shares of the company’s stock, valued at $171,576.32. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, CEO Craig A. Collard acquired 150,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The shares were purchased at an average cost of $0.92 per share, with a total value of $138,000.00. Following the acquisition, the chief executive officer now directly owns 186,496 shares in the company, valued at approximately $171,576.32. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Ira Duarte acquired 85,000 shares of the firm’s stock in a transaction on Thursday, November 16th. The stock was purchased at an average cost of $0.89 per share, for a total transaction of $75,650.00. Following the completion of the acquisition, the chief financial officer now owns 85,000 shares in the company, valued at $75,650. The disclosure for this purchase can be found here. 6.40% of the stock is owned by insiders.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Sei Investments Co. acquired a new stake in shares of Heron Therapeutics during the 1st quarter worth $27,000. State of Wyoming acquired a new stake in shares of Heron Therapeutics during the 2nd quarter worth $28,000. SG Americas Securities LLC acquired a new stake in shares of Heron Therapeutics during the 3rd quarter worth $31,000. Citigroup Inc. grew its holdings in shares of Heron Therapeutics by 195.6% during the 2nd quarter. Citigroup Inc. now owns 30,845 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 20,412 shares in the last quarter. Finally, Point72 Middle East FZE acquired a new stake in shares of Heron Therapeutics during the 4th quarter worth $37,000. 81.77% of the stock is owned by institutional investors and hedge funds.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc, a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration.
- Five stocks we like better than Heron Therapeutics
- Energy and Oil Stocks Explained
- 3 large caps with red hot RSIs with upside
- Most active stocks: Dollar volume vs share volume
- Johnson Controls International: Nothing but upside for investors
- 3 Monster Growth Stocks to Buy Now
- Unity Software’s resilient rebound post-earnings setback
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.